Dicer1 and associated conditions: Identification of at-risk individuals and recommended surveillance strategies

Kris Ann P. Schultz, Gretchen M. Williams, Junne Kamihara, Douglas R. Stewart, Anne K. Harris, Andrew J. Bauer, Joyce Turner, Rachana Shah, Katherine Schneider, Kami Wolfe Schneider, Ann Garrity Carr, Laura A. Harney, Shari Baldinger, A. Lindsay Frazier, Daniel Orbach, Dominik T. Schneider, David Malkin, Louis P. Dehner, Yoav H. Messinger, D. Ashley Hill

Research output: Contribution to journalReview article

62 Scopus citations

Abstract

Pathogenic germline DICER1 variants cause a hereditary cancer predisposition syndrome with a variety of manifestations. In addition to conferring increased cancer risks for pleuropulmonary blastoma (PPB) and ovarian sex cord–stro-mal tumors, particularly Sertoli–Leydig cell tumor, individuals with pathogenic germline DICER1 variants may also develop lung cysts, cystic nephroma, renal sarcoma and Wilms tumor, nodular hyperplasia of the thyroid, nasal chondromesenchymal hamartoma, ciliary body medulloepithelioma, genitourinary embryonal rhabdomyosarcoma, and brain tumors including pineoblastoma and pituitary blastoma. In May 2016, the International PPB Registry convened the inaugural International DICER1 Symposium to develop consensus testing and surveillance and treatment recommendations. Attendees from North America, Europe, and Russia provided expert representation from the disciplines of pediatric oncology, endocrinology, genetics, genetic counseling, radiology, pediatric surgery, pathology, and clinical research. Recommendations are provided for genetic testing; prenatal management; and surveillance for DICER1-associated pulmonary, renal, gynecologic, thyroid, ophthalmologic, otolaryngologic, and central nervous system tumors and gastrointestinal polyps. Risk for most DICER1-associated neoplasms is highest in early childhood and decreases in adulthood. Individual and caregiver education and judicious imaging-based surveillance are the primary recommended approaches. These testing and surveillance recommendations reflect a consensus of expert opinion and current literature. As DICER1 research expands, guidelines for screening and treatment will continue to be updated.

Original languageEnglish
Pages (from-to)2251-2261
Number of pages11
JournalClinical Cancer Research
Volume24
Issue number10
DOIs
StatePublished - May 15 2018

Fingerprint Dive into the research topics of 'Dicer1 and associated conditions: Identification of at-risk individuals and recommended surveillance strategies'. Together they form a unique fingerprint.

  • Cite this

    Schultz, K. A. P., Williams, G. M., Kamihara, J., Stewart, D. R., Harris, A. K., Bauer, A. J., Turner, J., Shah, R., Schneider, K., Schneider, K. W., Carr, A. G., Harney, L. A., Baldinger, S., Lindsay Frazier, A., Orbach, D., Schneider, D. T., Malkin, D., Dehner, L. P., Messinger, Y. H., & Ashley Hill, D. (2018). Dicer1 and associated conditions: Identification of at-risk individuals and recommended surveillance strategies. Clinical Cancer Research, 24(10), 2251-2261. https://doi.org/10.1158/1078-0432.CCR-17-3089